



Page numbers in *italics* indicate tables/exhibits.

A

Acceptance and commitment therapy (ACT), 31

Accreditation Council for Pharmacy Education, 171

Acetaminophen, 11, 139

Acupuncture, 8

Acute opioid overdose, treatment of, 73–74, 75–78

Acute pain. *See* Pain

Acute withdrawal, treatment of, 79–80

Addiction, 27–29

Affirmation, statements of, 50

Age and opioid use disorders (OUDs), 3

Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST), 44

Alcoholics Anonymous, 57, 153

Alcohol Use Disorders Identification Test (AUDIT), 44

Alcohol Use Disorders Identification Test (AUDIT-C), 45–47, 48

Alternative therapies for pain, 8–9

Ambulatory care settings. *See* Community care/ambulatory care settings

American Action Forum (AAF), 10

American Association of Colleges of Pharmacy (AACP), 163–164

SAPE report, 168–169

American College of Obstetricians and Gynecologists (ACOG), 126, 127

American Medical Association, 5

American Pain Society (APS), 5

American Pharmacists Association (APhA), 145

American Psychiatric Association, 28

American Society of Addiction Medicine (ASAM), 27–29, 126, 156

Amphetamines, detection time of, 59

Anterior cingulate cortex, 25

Assessment. *See* Screening

B

Barbiturates, detection time of, 59

Benzodiazepines, 3

 detection time of, 59

Betty Ford Consensus Panel, 32

Biomedical and psychosocial needs, addressing of, 64–65

Bio-psycho-social-spiritual OUD recovery programs, 98–99

“Black box” warnings, 3

Brain, the. *See* Neurobiology

Breastfeeding and neonatal abstinence syndrome (NAS), 139, 140

Brief intervention, 40, 44, 50–51

Buprenorphine

 for acute pain in patient with current active opioid use disorder, 96

 combination with naloxone, 80–81

 detection time of, 59

 long-acting formulations of, 81

 in medication-assisted therapy, 60, 62, 80–82

 metabolism of, 60

 for neonatal abstinence syndrome (NAS), 138

- in opioid treatment program (OTP), 98–99
- for pregnant women, 129, 130–131
- Burglaries and robberies, 111–112

C

-
- CAGE-AID, 47, 49
 - Cannabinoids, detection time of, 59
 - Celebrate Recovery, 57
 - Centers for Disease Control and Prevention (CDC), 2, 71, 72
 - on methadone, 7
 - Centers for Medicare & Medicaid Services (CMS), 8
 - Chiropractic manipulation, 9
 - Chronic/maintenance treatment options, 80–83
 - Chronic pain. *See* Pain
 - Clinical drug testing, 57–59
 - Clinical Drug Testing in Primary Care*, 59
 - Clinical indications for opioids in acute and chronic pain, 95
 - Clinical Opiate Withdrawal Scale (COWS), 79
 - Clonidine, 79, 139
 - Cocaine, 35
 - detection time of, 59
 - Codeine, metabolism of, 60
 - Code of Federal Regulations, 53, 106
 - Cognitive behavioral therapy (CBT), 31
 - Collaborative Approach to the Treatment of Pregnant Women with Opioid Use Disorders, A*, 136
 - Collateral damage of the opioid epidemic, 10–11
 - Community care/ambulatory care settings
 - caring for the patient with chronic pain and an SUD in, 61–62
 - clinical drug testing in, 57–59
 - controlled-substance agreements and monitoring, 54–55
 - counseling and support groups in, 57
 - education of patients and caregivers in, 59–61
 - medication checks in, 56
 - Community pharmacy practices in diversion, 104–108
 - Confidentiality of Alcohol and Drug Abuse Patient Records, CFR*, 53

- Controlled-substance agreements and monitoring, 54–55
- Controlled Substances Act of 1970, 4
- Core content development, 171–172
- Corticotropin releasing factor (CRF), 27
- Council of Economic Advisors, 4
- Counseling and support groups, 57
- Crack cocaine, 35
- Criminal justice system and opioid epidemic, 10
- Criteria and terminology used to define opioid use disorders, 38, 39
- Cross study, 153–154
- Cue-induced relapse, 26
- Curricular Guidelines for Pharmacy: Substance Abuse and Addictive Disease, 168–169
- Curriculum. *See* Education
- Cyclobenzaprine, 79

D

-
- Deaths. *See* Overdose, opioid
 - Department of Health and Human Services (DHHS), 1, 82
 - Detection and deterrence. *See also* Prescription drug monitoring programs (PDMPs)
 - community pharmacy practices and, 104–112
 - diversion strategies and, 104–116
 - of doctor and pharmacy shopping, 104–105
 - hospital practices and, 115–116
 - introduction to, 103
 - outpatient practices and, 113–114
 - and prevention of fraud and deception, 105–106
 - and prevention of prescriber-driven diversion, 108–111
 - and prevention of prescription forgeries, 106–108
 - rationales for medication diversion and, 103–104
 - of shortages, theft, and loss of prescription medications, 111–112
 - Detection times of common drugs of misuse, 58, 59
 - Detoxification, inpatient, 63–64
 - Diagnosis. *See* Screening